NasdaqGM - Delayed Quote • USD
Cellectis S.A. (CLLS)
At close: April 26 at 4:00 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Dec 2023) | Next Qtr. (Mar 2024) | Current Year (2023) | Next Year (2024) |
|---|---|---|---|---|
| No. of Analysts | 8 | 5 | 8 | 8 |
| Avg. Estimate | -0.22 | -0.31 | -1.27 | -1.12 |
| Low Estimate | -0.68 | -0.46 | -1.91 | -1.87 |
| High Estimate | 0.27 | -0.24 | -0.51 | -0.37 |
| Year Ago EPS | -0.59 | -0.58 | -2.33 | -1.27 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Dec 2023) | Next Qtr. (Mar 2024) | Current Year (2023) | Next Year (2024) |
|---|---|---|---|---|
| No. of Analysts | 7 | 5 | 8 | 7 |
| Avg. Estimate | 16.26M | 3.33M | 21.47M | 18.29M |
| Low Estimate | 1.64M | 1.64M | 8.8M | 8.8M |
| High Estimate | 45.39M | 7.5M | 52.64M | 40.6M |
| Year Ago Sales | 17.32M | 3.56M | 25.73M | 21.47M |
| Sales Growth (year/est) | -6.10% | -6.40% | -16.50% | -14.80% |
Earnings History
| CURRENCY IN USD | 12/31/2022 | 3/31/2023 | 6/30/2023 | 9/30/2023 |
|---|---|---|---|---|
| EPS Est. | -0.71 | -0.48 | -0.45 | -0.42 |
| EPS Actual | -0.59 | -0.58 | -0.19 | -0.31 |
| Difference | 0.12 | -0.1 | 0.26 | 0.11 |
| Surprise % | 16.90% | -20.80% | 57.80% | 26.20% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Dec 2023) | Next Qtr. (Mar 2024) | Current Year (2023) | Next Year (2024) |
|---|---|---|---|---|
| Current Estimate | -0.22 | -0.31 | -1.27 | -1.12 |
| 7 Days Ago | -0.22 | -0.31 | -1.27 | -1.12 |
| 30 Days Ago | -0.22 | -0.31 | -1.27 | -1.12 |
| 60 Days Ago | -0.22 | -0.31 | -1.27 | -1.12 |
| 90 Days Ago | -0.29 | -0.32 | -1.27 | -1.12 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Dec 2023) | Next Qtr. (Mar 2024) | Current Year (2023) | Next Year (2024) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | CLLS | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 62.70% | -- | -- | 6.50% |
| Next Qtr. | 46.60% | -- | -- | 12.00% |
| Current Year | 45.50% | -- | -- | 5.30% |
| Next Year | 11.80% | -- | -- | 13.10% |
| Next 5 Years (per annum) | -- | -- | -- | 11.09% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Reiterates | JMP Securities: Market Outperform to Market Outperform | 11/1/2023 |
| Reiterates | Oppenheimer: Outperform to Outperform | 8/8/2023 |
| Reiterates | JMP Securities: Market Outperform to Market Outperform | 8/7/2023 |
| Maintains | Citigroup: Buy | 4/5/2023 |
| Maintains | Oppenheimer: Outperform | 3/13/2023 |
| Reiterates | JMP Securities: Market Outperform | 3/13/2023 |
Related Tickers
ALLO Allogene Therapeutics, Inc.
2.8900
+1.23%
AUTL Autolus Therapeutics plc
4.0000
-1.96%
GNFT Genfit S.A.
3.4900
+2.35%
FATE Fate Therapeutics, Inc.
3.8000
-1.81%
LPCN Lipocine Inc.
4.7977
+6.14%
LPTX Leap Therapeutics, Inc.
3.2500
+2.52%
ATRA Atara Biotherapeutics, Inc.
0.6900
-1.40%
CRBU Caribou Biosciences, Inc.
3.7100
-1.33%
MRSN Mersana Therapeutics, Inc.
2.9400
+3.16%
GBIO Generation Bio Co.
2.9000
-3.65%